UBS analyst Trung Huynh raised the firm’s price target on Insmed (INSM) to $223 from $194 and keeps a Buy rating on the shares. Insmed posted an “impressive” launch update for Brinsupri, the analyst tells investors in a research note. At these levels, the stock is not pricing in much for pipeline upside from Chronic Rhinosinusitis without Nasal Polyps, hidradenitis suppurativa for brensocatib and Treprostinil Palmitil Inhalation Powder indications, UBS says.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Strong Buy Rating for Insmed Driven by Brinsupri’s Success and Promising Pipeline
- Insmed price target raised to $217 from $171 at Wells Fargo
- Insmed’s Q3 2025 Earnings Highlight Growth and Expansion
- Strong Financial Performance and Promising Pipeline Drive Buy Rating for Insmed
- Insmed’s Strong Financial Performance and Promising Product Launches Reinforce Buy Rating